Bioavailability of Duloxetine 60 mg in Feeding Conditions

Phase 1, randomised, open-label trial of duloxetine in major depressive disorder (MDD), generalized anxiety disorder (GAD), fibromyalgia (FM) and 2 more (2 arms), sponsored by Laboratorios Andromaco S.A. Primary endpoints: Area under the plasma concentration-time curve from time zero to 72 hours, Area under the plasma concentration-time curve from time zero to time t and 2 more. Started Feb 2021; status: completed.